Patents Assigned to Catalyst Assets LLC
  • Patent number: 8383343
    Abstract: The invention encompasses methods for enriching for and identifying a polymorphism within a nucleic acid sample either by separating a subset of a nucleic acid sample or by selectively replicating a subset of a nucleic acid sample such that the polymorphism is contained within a nucleic acid population with reduced complexity, and then identifying the polymorphism within the enriched nucleic acid sample.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: February 26, 2013
    Assignee: Catalyst Assets LLC
    Inventor: Joseph A. Sorge
  • Patent number: 8338107
    Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: December 25, 2012
    Assignees: Scripps Research Institute, Medical Research Institute, Catalyst Assets LLC
    Inventors: William D. Huse, Gregory P. Winter, Lutz Riechmann, Joseph A. Sorge, Richard A. Lerner
  • Patent number: 8263338
    Abstract: The invention encompasses methods for enriching for and identifying a polymorphism within a nucleic acid sample either by separating a subset of a nucleic acid sample or by selectively replicating a subset of a nucleic acid sample such that the polymorphism is contained within a nucleic acid population with reduced complexity, and then identifying the polymorphism within the enriched nucleic acid sample.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: September 11, 2012
    Assignee: Catalyst Assets LLC
    Inventor: Joseph A. Sorge
  • Publication number: 20110312516
    Abstract: The present invention is based, at least in part, upon discovery of a number of miRNAs having expression that significantly correlates with bladder cancer, including certain stages or types of bladder cancer, as well as with bladder cancer survival and/or responsiveness to bladder cancer therapies. Accordingly, the present invention features the identification and use of miRNAs to detect, diagnose and/or predict the course, progression or therapy responsiveness of bladder cancer. Kits for performing such assessments, and for administering therapeutic agents to subjects diagnosed with bladder cancer or certain forms of bladder cancer using the methods of the invention, are also featured.
    Type: Application
    Filed: March 18, 2011
    Publication date: December 22, 2011
    Applicant: Catalyst Assets LLC
    Inventors: Torben F. Orntoft, Lars D. Andersen